| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/21/2014 | US8633177 Nitroxyl (HNO) releasing compounds and uses thereof in treating diseases |
| 01/21/2014 | US8633176 Pharmaceutical formulation containing choline alfoscerate |
| 01/21/2014 | US8633175 Compounds as antagonists or inverse agonists at opioid receptors |
| 01/21/2014 | US8633174 Compounds for use in the treatment of cancer |
| 01/21/2014 | US8633173 Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives |
| 01/21/2014 | US8633172 Cyclodextrin nanotechnology for ophthalmic drug delivery |
| 01/21/2014 | US8633171 Transparent oil gelling system |
| 01/21/2014 | US8633170 Therapy-enhancing glucan |
| 01/21/2014 | US8633169 Antiviral topical formulations in the form of a bio-adhesive gel |
| 01/21/2014 | US8633168 Inhibitors of S-adenosyl-L-methionine decarboxylase |
| 01/21/2014 | US8633167 Method for the protection of trees |
| 01/21/2014 | US8633166 Methicillin-resistant Staphylococcus aureus active metabolites |
| 01/21/2014 | US8633165 Neuroprotective effects of 2DG in traumatic brain injury |
| 01/21/2014 | US8633149 Targeting PAX2 for the treatment of breast cancer |
| 01/21/2014 | US8633134 Substituted amidine compounds for combating animal pests |
| 01/21/2014 | US8633026 Cytokine induction of selectin ligands on cells |
| 01/21/2014 | US8632997 RNA sequence-specific mediators of RNA interference |
| 01/21/2014 | US8632820 Compositions for achieving a therapeutic effect in an anatomical structure |
| 01/21/2014 | US8632813 Prostaglandin compositions and methods for the treatment of vasospasm |
| 01/21/2014 | US8632808 Taste-masking solid preparation of pioglitazone |
| 01/21/2014 | US8632807 Pharmaceutical composition |
| 01/21/2014 | US8632804 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
| 01/21/2014 | US8632801 Stable therapeutic formulations |
| 01/21/2014 | US8632792 Cooling sensation agent composition and sensory stimulation agent composition |
| 01/21/2014 | US8632791 Silicone microparticles comprising silicone elastomer spherical microparticles coated with polyorganosilsesquioxane, and method of producing same |
| 01/21/2014 | US8632788 Parenteral formulation for epothilone analogs |
| 01/21/2014 | US8632787 Methods using immunomodulatory compounds for treatment of certain leukemias |
| 01/21/2014 | US8632767 3-[1-(3-haloalkyl)triazolyl]phenyl sulphide derivatives as acaricides and insecticides |
| 01/21/2014 | US8632763 Use of a copolymer in the form of a solubiliser for a poorly water-soluble compound |
| 01/21/2014 | US8632760 Method of enhancing hair growth |
| 01/21/2014 | US8632750 Methods for recommending neurophysiological disorder therapy |
| 01/21/2014 | CA2789001C Method for treatment of lacto-n-biose-containing solution |
| 01/21/2014 | CA2774046C Compositions comprising phenylsulfamic acids and their use for treating colitis |
| 01/21/2014 | CA2745782C Pharmaceutical compositions and uses for peptide treatment |
| 01/21/2014 | CA2734284C Pyrazolone derivative formulations |
| 01/21/2014 | CA2711263C Compositions and methods for the treatment of xerostomia |
| 01/21/2014 | CA2691442C Antiviral compounds |
| 01/21/2014 | CA2671000C Method for suppressing coloring of adhesive preparation containing donepezil and method for reducing amounts of donepezil-related substances formed |
| 01/21/2014 | CA2657096C Human protein tyrosine phosphatase inhibitors and methods of use |
| 01/21/2014 | CA2639921C Microspheres comprising nanocapsules containing a lipophilic drug |
| 01/21/2014 | CA2637941C Anti-infective solution comprising a compound of pyrido(3,2,1-ij)-benzoxadiazine type |
| 01/21/2014 | CA2631123C Composition in the form of a spray containing a corticoid and an oil phase |
| 01/21/2014 | CA2628747C Combinations of hormone therapy agents and metalloprotease inhibitors for the treatment of cancer |
| 01/21/2014 | CA2626797C Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| 01/21/2014 | CA2622000C Quinolines and their therapeutic use |
| 01/21/2014 | CA2617147C Formulation of radioprotective .alpha.,.beta. unsaturated aryl sulfones |
| 01/21/2014 | CA2616941C Combination of itriglumide and proton pump inhibitors in the treatment of gastrointestinal and related disorders |
| 01/21/2014 | CA2616721C Methods for treating substance-related disorders |
| 01/21/2014 | CA2609288C Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor xa inhibitors |
| 01/21/2014 | CA2605050C Histone deacetylase inhibitors |
| 01/21/2014 | CA2603249C Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators |
| 01/21/2014 | CA2600637C Tetrahydro- and dihydroquinazolinones |
| 01/21/2014 | CA2597384C Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases |
| 01/21/2014 | CA2586106C Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseases |
| 01/21/2014 | CA2580534C 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives and use thereof as ppar modulators |
| 01/21/2014 | CA2568504C Local vascular delivery of p13 kinase inhibitors alone or in combination with sirolimus to prevent restinosis following vascular injury |
| 01/21/2014 | CA2555149C Method of treating and diagnosing sleep disordered breathing using zonisamide and means for carrying out the method |
| 01/21/2014 | CA2522637C Modified irna agents |
| 01/21/2014 | CA2486473C Vaginal care composition |
| 01/21/2014 | CA2484398C Method for reducing pain using oncolytic viruses |
| 01/21/2014 | CA2446723C Antibodies that immunospecifically bind to trail receptors |
| 01/21/2014 | CA2427257C Expression vectors able to elicit improved immune response and methods of using same |
| 01/21/2014 | CA2418014C Immunotherapy for chronic myelocytic leukemia |
| 01/21/2014 | CA2371995C Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| 01/21/2014 | CA2359317C Method of treating restenosis by antisense targeting of c-myc |
| 01/21/2014 | CA2341763C Antigenic peptides of aglyco 10b and antibodies thereto |
| 01/21/2014 | CA2236868C Conditionally replicating viral vectors and their use |
| 01/20/2014 | CA2783634A1 Dimer diol compositions as substitutes of body fluids |
| 01/19/2014 | CA2785303A1 Method for the non-surgical treatment of lipodystrophy in a retrovirus-infected individual |
| 01/16/2014 | WO2014012117A1 Compositions and methods for localized drug delivery through mammary papillae |
| 01/16/2014 | WO2014012094A2 Tetracycline compounds for treating neurodegenerative disorders |
| 01/16/2014 | WO2014012090A1 Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof |
| 01/16/2014 | WO2014012084A1 Treatment of diabetes mellitus with carvedilol |
| 01/16/2014 | WO2014012063A1 Pharmaceutical dosage forms comprising ecopipam free base or pharmaceutically acceptable salts thereof |
| 01/16/2014 | WO2014012034A1 Fused benzazepines for treatment of tourette's syndrome |
| 01/16/2014 | WO2014012014A1 Methods and products related to protozoan disease |
| 01/16/2014 | WO2014012000A2 No-releasing guanidine-coxib anti-cancer agents |
| 01/16/2014 | WO2014011974A1 Imidazotriazinecarbonitriles useful as kinase inhibitors |
| 01/16/2014 | WO2014011973A2 Quinazolinone-based oncogenic-ras-selective lethal compounds and their use |
| 01/16/2014 | WO2014011949A2 Neuroprotective cb2 receptor agonists |
| 01/16/2014 | WO2014011926A1 Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| 01/16/2014 | WO2014011917A2 A method of inhibiting tau phosphorylation |
| 01/16/2014 | WO2014011902A1 Irak inhibitors and uses thereof |
| 01/16/2014 | WO2014011875A1 Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof |
| 01/16/2014 | WO2014011863A1 Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane |
| 01/16/2014 | WO2014011857A1 Matrix and layer compositions for protection of bioactives |
| 01/16/2014 | WO2014011830A1 Extended release, abuse deterrent pharmaceutical compositions |
| 01/16/2014 | WO2014011815A2 Methods of inducing sedation |
| 01/16/2014 | WO2014011814A1 Tri-salt form of metformin |
| 01/16/2014 | WO2014011769A1 Macrocyclic compounds as hiv integrase inhibitors |
| 01/16/2014 | WO2014011768A1 Anti-anxiety treatment |
| 01/16/2014 | WO2014011754A1 Novel 1, 4-benzoxazinone compounds |
| 01/16/2014 | WO2014011750A1 Laquinimod formulations without alkalizing agent |
| 01/16/2014 | WO2014011713A2 Anti-proliferative compounds and uses thereof |
| 01/16/2014 | WO2014011712A1 Iap antagonists |
| 01/16/2014 | WO2014011680A2 Tetrahydro-isohumulone derivatives, methods of making and using |
| 01/16/2014 | WO2014011676A1 Prevention of alcohol reaction with dietary supplements |
| 01/16/2014 | WO2014011663A1 Inhibitors of bacterial diguanylate cyclase |
| 01/16/2014 | WO2014011636A1 Novel medical countermeasure for first responder use in mass casualty thermal and/or radiological burn injury event |
| 01/16/2014 | WO2014011629A1 Stable aqueous formulations of etanercept |